Results 51 to 60 of about 32,071 (158)
Scientific Reports, 2021 Human coronavirus NL63 (HCoV-NL63) mainly affects young children and immunocompromised patients, causing morbidity and mortality in a subset of patients.
Yining Wang +9 more
doaj +1 more source
BMC Chemistry, 2023 Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir ...
Afnan S. Batubara +4 more
doaj +1 more source
The Journal of Pathology, EarlyView.Abstract Post‐COVID‐19 condition (PCC), also known as long COVID, is a complex multiple organ system condition that can develop and persist for months after acute COVID‐19. PCC encompasses a wide range of symptoms, resulting in heterogeneous clinical manifestations. These manifestations likely arise from diverse underlying pathophysiological mechanisms,
Larissa E Vlaming‐van Eijk +5 more
wiley +1 more source
Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis
Journal of Investigative Medicine High Impact Case Reports, 2023 End-stage kidney disease (ESKD) has been shown to be correlated with an increased risk of COVID-19 infection and mortality. Remdesivir is an effective non-EUA U.S.
Ryan Geffin MD +6 more
doaj +1 more source
International Journal of Health Care and Biological Sciences, 2021 Remdesivir is an investigational broad-spectrum small-molecule antiviral drug that has confirmed interest in the direction of RNA viruses in numerous families, which encompass Coronaviridae (alongside aspect SARS-CoV, MERS-CoV, and lines of bat coronaviruses able to infecting human respiratory epithelial cells), Paramyxoviridae (alongside aspect Nipah ...
Venkata Niharika Daka +4 more
openaire +3 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Clostridioides difficile infection (CDI) represents a significant health risk to pediatric stem cell transplant (SCT) patients. In these patients, recurrent CDI is common, requiring prolonged antibiotic usage and increased hospitalization. Bezlotoxumab, a monoclonal antibody that targets the toxin responsible for CDI, has demonstrated efficacy
Aaron E. Fan +8 more
wiley +1 more source
Infectious Diseases of Poverty, 2023 Background Remdesivir is being studied and used to treat coronavirus disease 2019 (COVID-19). This study aimed to systematically identify, critically evaluate, and summarize the findings of the studies on the cost-effectiveness of remdesivir in the ...
Aziz Rezapour +7 more
doaj +1 more source
Viral Dynamic Models During COVID‐19: Are We Ready for the Next Pandemic?
CPT: Pharmacometrics &Systems Pharmacology, EarlyView.ABSTRACT Mathematical models have been used for about 30 years to improve our understanding of virus‐host interaction, in particular during chronic infections. During the COVID‐19 pandemic, these models have been used to provide insights into the natural history of acute SARS‐CoV‐2 infection, optimize antiviral treatment strategies, understand factors ...
Aurelien Marc +4 more
wiley +1 more source
FASEB BioAdvances, EarlyView.This randomized, placebo‐controlled trial assessed the effects of NAD augmentation by administration of oral β Nicotinamide Mononucleotide (β NMN) 1.0 g twice daily or placebo for 14 days in adult patients hospitalized with COVID‐19 and acute kidney injury on blood NAD, plasma levels of NAD metabolites, biomarkers of acute kidney injury, inflammation ...
Karol M. Pencina +15 more
wiley +1 more source
iScience, 2021 Summary: The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of
Aditya K. Padhi +3 more
doaj